This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Hartvig, P. Articles by Wagenius, G. Search for Related Content PubMed PubMed Citation Articles by Hartvig, P. Articles by Wagenius, G. Social Bookmarking                         What's this?

Fatigue in cancer patients treated with cytotoxic drugs

Hospital Pharmacy, University Hospital, Uppsala, Sweden

Johan Aulin, MSc in pharmacy

Hospital Pharmacy, University Hospital, Uppsala, Department of Pharmacokinetics and Drug Therapy, Uppsala University, Uppsala, Sweden

Matilda Hugerth, MSc in pharmacy

Department of Pharmacokinetics and Drug Therapy, Uppsala University, Uppsala, Sweden

Sofia Wallenberg, MSc in pharmacy

Department of Pharmacokinetics and Drug Therapy, Uppsala University, Uppsala, Sweden

Gunnar Wagenius, MD, PhD

Department of Oncology, University Hospital, Uppsala, Sweden

Study objectives. Cancer-related fatigue is a significant and distressing problem for the cancer patient, affecting their physical and psychosocial function negatively, and reducing their quality of life. The aims of this study were to assess frequency, severity, and the consequence of fatigue in cancer outpatients receiving cytotoxic drugs, using an existing international fatigue scale applied for Swedish use.

Methods. The study used a non-randomized, prospective design to evaluate fatigue and its impact on quality of life in outpatients receiving cytotoxic drugs. Once a week, 147 cancer patients, in an outpatient ward for cytotoxic drug administration, filled out questionnaires containing 13 items from the Fatigue Symptom Inventory (FSI), and five additional questions.

Results. Prevalence of fatigue was 92% in the week after all patients had received cytotoxic drugs, and patients were statistically significantly more fatigued during than before treatment. The degree of fatigue was highest the week after treatment, and declined over the following week. Other symptoms, especially depressed mood, showed a strong correlation with cancer and cytotoxic-induced fatigue. Lung and breast cancer patients experienced the highest degree of fatigue. Some cytotoxic drug regimens were, apart from the underlying disease, associated with high fatigue scores, eg, those with cyclophosphamide or gemcitabine. Patients not receiving first line treatment scored significantly higher fatigue with more influence on daily living.

Conclusion. The study verified that fatigue is a common side effect, and affects quality of life negatively, even for outpatients receiving cytotoxic drugs. The clinical oncology pharmacist must inform patients that a severe tiredness, fatigue, may follow cytotoxic drug administration.

Key Words: cytotoxic drugs • fatigue • quality of life • self-report • side effects

Journal of Oncology Pharmacy Practice, Vol. 12, No. 3, 155-164 (2006)
DOI: 10.1177/1078155206070774


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. C. Higgins, G. H. Montgomery, G. Raptis, and D. H. Bovbjerg Effect of Pretreatment Distress on Daily Fatigue After Chemotherapy for Breast Cancer J. Oncol. Pract, March 1, 2008; 4(2): 59 - 63. [Abstract] [Full Text] [PDF]

				P. Hartvig, J. Aulin, S. Wallenberg, and G. Wagenius Physical exercise for cytotoxic drug-induced fatigue Journal of Oncology Pharmacy Practice, December 1, 2006; 12(4): 183 - 191. [Abstract] [PDF]